Company: IMRX
Filing Date: 2025-09-25
Form Type: 8-K
Source: 0001104659-25-093436
Chunk: 3

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 8-K
Item: Item 8.01
Chunk 3
---
Item 8.01. Other Events.

On August 13, 2025, the Company entered into an equity
distribution agreement with Piper Sandler & Co. relating to the sale of shares of the Company's Class A common stock having a
maximum aggregate offering price of up to $100,000,000 from time to time pursuant to at-the-market transactions (the "ATM Program").
As of the date of this report, the Company has not sold any shares under the ATM Program.

In connection with the Offering, the Company (i) reduced the
maximum aggregate offering price for sales of shares pursuant to at-the-market transactions under the ATM Program by $1,250,007 (the
"Reduced Amount"), resulting in a new maximum aggregate offering price of up to $98,749,993 under the ATM Program, and (ii)
suspended the ATM Program and terminated the continuous offering under the ATM Program, in each case, as to the Reduced Amount.

Forward-Looking Statements